• Recruiting

NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

Updated: Sep 27


NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

icon study

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)


Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.


Sponsor

Amsterdam UMC, location VUmc


Collaborator

Celgene


Location

Netherlands

 

ClinicalTrials.gov Identifier: NCT04392037


Official Title: A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study


First Posted : May 18, 2020


Click here for details on Clinicaltrials.gov

 

Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

 

Location

Europe

Netherlands






Posts Archive